Clinical trials: Chidamide
Acute Myeloid Leukemia (Relapsed/Refractory)
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.
- Trial name
- NCT05951855
- Testing
- Selinexor, Chidamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
T Cell Non-Hodgkin's Lymphoma
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide， epirubicin,vindesine, etoposide and prednisone) regimen as…
- Trial name
- NCT02987244
- Testing
- Chidamide, Cyclophosphamide, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Cutaneous T-cell Lymphoma (CTCL)
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma.
- Trial name
- NCT07754890
- Testing
- golidocitinib, Chidamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
B-cell non-Hodgkin lymphoma (B-NHL) is one of the most common malignancies in China, with approximately 100,000 new cases diagnosed annually.
- Trial name
- NCT07489989
- Testing
- CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daihong Liu
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Chidamide, Lymphoma, B-Cell
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined with R-GDP （rituximab/gemcitabine/dexamethasone/cisplatin）in treating Patients with relapsed or refractory Diffuse Large B-cell Lymphoma…
- Conditions
- Chidamide, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm by Histology
- Trial name
- NCT03373019
- Testing
- Chidamide combined with R-GDP
- Where
- 2 sites in China
- Volunteers
- 63 people
- Sponsor
- Fudan University
Relapsed/Refractory Peripheral T-cell Lymphoma
Chi-GVM Regimen for the Treatment of R/R PTCL
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative diseases caused by mature T cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL).
- Trial name
- NCT06211881
- Testing
- Chi-GVM
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral T Cell Lymphoma
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono-therapy in PTCL. The combination of duvelisib and romidepsin is highly active for relapsed and refractory PTCLs.
- Trial name
- NCT06083701
- Testing
- Linperlisib in combined with Chidamide
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
- Trial name
- NCT07511114
- Testing
- C-Pola-R-CHP+X, CR-CHOP
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-cell Lymphoma
Chidamide Plus R-CHOP in Elderly DLBCL
This is a prospective, single-arm, open-label phase II study of Chidamide in combination with R-CHOP in the treatment of de novo, elderly, high-risk diffuse large B cell lymphoma patients.
- Trial name
- NCT02753647
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Ruijin Hospital
APL
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment.
- Trial name
- NCT05881265
- Testing
- Chidamide+venetoclax
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
HR+/HER2- Advanced Breast Cancer, Targeted Therapy
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-)…
- Trial name
- NCT05983107
- Testing
- Everolimus, Chidamide, Endocrine therapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Multiple Myeloma
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
- Trial name
- NCT03605056
- Testing
- chidamide, lenalidomide, dexamethasone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peng Liu
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
DLBCL
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell…
- Trial name
- NCT06779435
- Testing
- Low intensity treatment options, Conventional immunochemotherapy regimen
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).
- Trial name
- NCT03245905
- Testing
- Chidamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
This is a single-center, open-label, phase II clinical trial designed to evaluate the efficacy and safety of chidamide in combination with chemotherapy and immunotherapy as a first-line treatment for patients with advanced…
- Trial name
- NCT07570849
- Testing
- Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Peripheral T-cell Lymphoma
Linperlisib Combined With Chidamide in Patients With PTCL
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06421948
- Testing
- Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Yanyan Liu
Metastatic Pancreatic Cancer
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT06951997
- Testing
- QL1706, Chidamide, Gemcitabine
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HIV-1 Infection
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo…
- Trial name
- NCT05056974
- Testing
- UB-421, chidamide
- Where
- Taiwan
- Volunteers
- 11 people
- Sponsor
- United BioPharma